Newcourt Acquisition Corp. (NCAC) Closes Psyence Deal
by Marlena Haddad on 2024-01-25 at 6:14pm

Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.

Shareholders previously approved the combination during a special meeting held on January 18.

In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.

In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.

Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.

The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.

Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.


ADVISORS

  • Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
  • WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
  • Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
  • McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
Recent Posts
by Kristi Marvin on 2024-07-13 at 11:44am

Terms Tracker for the Week Ending July 12, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. The rush is on to price the SPAC IPOs with anchor investors while they still can and Cantor managed to push out two of them...

by Nicholas Alan Clayton on 2024-07-12 at 8:17am

At the SPAC of Dawn With all eyes on the fireworks both literal and figurative in Western politics this month, July has hosted a relative drought of new business combinations with just one so far announced. But, there are flashes on the horizon as three SPACs signed letters of intent to combine with targets in...

by Nicholas Alan Clayton on 2024-07-11 at 4:59pm

Launch One Acquisition Corp. announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “LPAAU”, Friday, July 12, 2024. The new SPAC aims to combine with an established company of scale in healthcare and healthcare-related industries and, in particular, life sciences, globally. Launch...

by Nicholas Alan Clayton on 2024-07-11 at 8:24am

At the SPAC of Dawn As the market awaits the reading for the US’ CPI numbers for June at 8:30 am ET, SPAC teams are increasingly looking outside of the US for filing their initial corporate documents. So far, none of the 34 SPACs that have filed for IPOs in 2024 have been domiciled in...

by Nicholas Alan Clayton on 2024-07-10 at 8:11am

At the SPAC of Dawn Wednesday is set to be potentially the busiest day of the week for SPACs with three extension votes and a completion vote for investors to get through. The day also holds the possibility of being the month’s first debut of multiple SPACs at once as SIM I (NASDAQ:SIMAU) priced overnight...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved